These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test. Pillidge K; Porter AJ; Young JW; Stanford SC J Psychopharmacol; 2016 Sep; 30(9):837-47. PubMed ID: 27097734 [TBL] [Abstract][Full Text] [Related]
4. Overview of animal models of attention deficit hyperactivity disorder (ADHD). Russell VA Curr Protoc Neurosci; 2011 Jan; Chapter 9():Unit9.35. PubMed ID: 21207367 [TBL] [Abstract][Full Text] [Related]
5. A lack of functional NK1 receptors explains most, but not all, abnormal behaviours of NK1R-/- mice(1). Porter AJ; Pillidge K; Tsai YC; Dudley JA; Hunt SP; Peirson SN; Brown LA; Stanford SC Genes Brain Behav; 2015 Feb; 14(2):189-99. PubMed ID: 25558794 [TBL] [Abstract][Full Text] [Related]
6. Rodent models of attention-deficit/hyperactivity disorder. Sagvolden T; Russell VA; Aase H; Johansen EB; Farshbaf M Biol Psychiatry; 2005 Jun; 57(11):1239-47. PubMed ID: 15949994 [TBL] [Abstract][Full Text] [Related]
7. The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder. Pillidge K; Heal DJ; Stanford SC J Psychopharmacol; 2016 Sep; 30(9):848-55. PubMed ID: 27462087 [TBL] [Abstract][Full Text] [Related]
8. Animal models of attention-deficit hyperactivity disorder. Davids E; Zhang K; Tarazi FI; Baldessarini RJ Brain Res Brain Res Rev; 2003 Apr; 42(1):1-21. PubMed ID: 12668288 [TBL] [Abstract][Full Text] [Related]
9. Differences in the performance of NK1R-/- ('knockout') and wildtype mice in the 5‑Choice Continuous Performance Test. Porter AJ; Pillidge K; Stanford SC; Young JW Behav Brain Res; 2016 Feb; 298(Pt B):268-77. PubMed ID: 26522842 [TBL] [Abstract][Full Text] [Related]
10. The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder. Avale ME; Falzone TL; Gelman DM; Low MJ; Grandy DK; Rubinstein M Mol Psychiatry; 2004 Jul; 9(7):718-26. PubMed ID: 14699433 [TBL] [Abstract][Full Text] [Related]
11. Rodent models of ADHD. Fan X; Bruno KJ; Hess EJ Curr Top Behav Neurosci; 2012; 9():273-300. PubMed ID: 21516392 [TBL] [Abstract][Full Text] [Related]
12. Rodent models of attention-deficit hyperactivity disorder: An updated framework for model validation and therapeutic drug discovery. Kantak KM Pharmacol Biochem Behav; 2022 May; 216():173378. PubMed ID: 35367465 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the validity of the use of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder in males and females. Bayless DW; Perez MC; Daniel JM Behav Brain Res; 2015 Jun; 286():85-92. PubMed ID: 25724583 [TBL] [Abstract][Full Text] [Related]
14. Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder. Moran-Gates T; Zhang K; Baldessarini RJ; Tarazi FI Int J Neuropsychopharmacol; 2005 Sep; 8(3):439-44. PubMed ID: 15817135 [TBL] [Abstract][Full Text] [Related]
15. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. van der Kooij MA; Glennon JC Neurosci Biobehav Rev; 2007; 31(4):597-618. PubMed ID: 17316796 [TBL] [Abstract][Full Text] [Related]
17. Neonatal 6-OHDA Lesion Model in Mouse Induces Cognitive Dysfunctions of Attention-Deficit/Hyperactivity Disorder (ADHD) During Young Age. Bouchatta O; Manouze H; Ba-M'Hamed S; Landry M; Bennis M Front Behav Neurosci; 2020; 14():27. PubMed ID: 32174817 [TBL] [Abstract][Full Text] [Related]
18. Dissociation of impulsivity and aggression in mice deficient for the ADHD risk gene Adgrl3: Evidence for dopamine transporter dysregulation. Mortimer N; Ganster T; O'Leary A; Popp S; Freudenberg F; Reif A; Soler Artigas M; Ribasés M; Ramos-Quiroga JA; Lesch KP; Rivero O Neuropharmacology; 2019 Sep; 156():107557. PubMed ID: 30849401 [TBL] [Abstract][Full Text] [Related]
19. Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD). de la Peña JB; Dela Peña IJ; Custodio RJ; Botanas CJ; Kim HJ; Cheong JH Mol Neurobiol; 2018 May; 55(5):3739-3754. PubMed ID: 28534274 [TBL] [Abstract][Full Text] [Related]
20. Behavioral and pharmacological studies on the validation of a new animal model for attention deficit hyperactivity disorder. Puumala T; Ruotsalainen S; Jäkälä P; Koivisto E; Riekkinen P; Sirviö J Neurobiol Learn Mem; 1996 Sep; 66(2):198-211. PubMed ID: 8946412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]